Logo image of TALEA.MI

TALEA GROUP SPA (TALEA.MI) Stock Fundamental Analysis

BIT:TALEA - Euronext Milan - IT0005378333 - Common Stock - Currency: EUR

5  -0.14 (-2.72%)

Fundamental Rating

3

TALEA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 26 industry peers in the Consumer Staples Distribution & Retail industry. TALEA has a bad profitability rating. Also its financial health evaluation is rather negative. TALEA is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year TALEA has reported negative net income.
TALEA had a positive operating cash flow in the past year.
In the past 5 years TALEA always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: TALEA reported negative operating cash flow in multiple years.
TALEA.MI Yearly Net Income VS EBIT VS OCF VS FCFTALEA.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 -5M -10M

1.2 Ratios

With a Return On Assets value of -6.06%, TALEA is not doing good in the industry: 84.62% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -29.09%, TALEA is doing worse than 84.62% of the companies in the same industry.
Industry RankSector Rank
ROA -6.06%
ROE -29.09%
ROIC N/A
ROA(3y)-2.01%
ROA(5y)-1.7%
ROE(3y)-8.9%
ROE(5y)-7.83%
ROIC(3y)N/A
ROIC(5y)N/A
TALEA.MI Yearly ROA, ROE, ROICTALEA.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 -50

1.3 Margins

TALEA has a better Gross Margin (28.25%) than 80.77% of its industry peers.
TALEA's Gross Margin has improved in the last couple of years.
TALEA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 28.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.79%
GM growth 5Y13.49%
TALEA.MI Yearly Profit, Operating, Gross MarginsTALEA.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 10 20 30

More info and screens

1

2. Health

2.1 Basic Checks

TALEA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TALEA has been increased compared to 1 year ago.
The number of shares outstanding for TALEA has been increased compared to 5 years ago.
The debt/assets ratio for TALEA is higher compared to a year ago.
TALEA.MI Yearly Shares OutstandingTALEA.MI Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M
TALEA.MI Yearly Total Debt VS Total AssetsTALEA.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 50M 100M

2.2 Solvency

Based on the Altman-Z score of 1.03, we must say that TALEA is in the distress zone and has some risk of bankruptcy.
TALEA has a Altman-Z score of 1.03. This is amonst the worse of the industry: TALEA underperforms 92.31% of its industry peers.
A Debt/Equity ratio of 0.73 indicates that TALEA is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.73, TALEA is in the better half of the industry, outperforming 61.54% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF N/A
Altman-Z 1.03
ROIC/WACCN/A
WACC6.01%
TALEA.MI Yearly LT Debt VS Equity VS FCFTALEA.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M 30M 40M

2.3 Liquidity

A Current Ratio of 0.64 indicates that TALEA may have some problems paying its short term obligations.
With a Current ratio value of 0.64, TALEA is not doing good in the industry: 88.46% of the companies in the same industry are doing better.
A Quick Ratio of 0.27 indicates that TALEA may have some problems paying its short term obligations.
The Quick ratio of TALEA (0.27) is worse than 84.62% of its industry peers.
Industry RankSector Rank
Current Ratio 0.64
Quick Ratio 0.27
TALEA.MI Yearly Current Assets VS Current LiabilitesTALEA.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

5

3. Growth

3.1 Past

TALEA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -267.46%.
Looking at the last year, TALEA shows a small growth in Revenue. The Revenue has grown by 0.85% in the last year.
Measured over the past years, TALEA shows a very strong growth in Revenue. The Revenue has been growing by 39.60% on average per year.
EPS 1Y (TTM)-267.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-103.65%
Revenue 1Y (TTM)0.85%
Revenue growth 3Y27.06%
Revenue growth 5Y39.6%
Sales Q2Q%8.36%

3.2 Future

The Earnings Per Share is expected to grow by 39.40% on average over the next years. This is a very strong growth
Based on estimates for the next years, TALEA will show a quite strong growth in Revenue. The Revenue will grow by 17.56% on average per year.
EPS Next Y77.38%
EPS Next 2Y53.93%
EPS Next 3Y39.4%
EPS Next 5YN/A
Revenue Next Year23.61%
Revenue Next 2Y21.79%
Revenue Next 3Y17.56%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
TALEA.MI Yearly Revenue VS EstimatesTALEA.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M 200M
TALEA.MI Yearly EPS VS EstimatesTALEA.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.5 -0.5 -1

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

TALEA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 11.99, which indicates a very decent valuation of TALEA.
61.54% of the companies in the same industry are more expensive than TALEA, based on the Price/Forward Earnings ratio.
TALEA's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.70.
Industry RankSector Rank
PE N/A
Fwd PE 11.99
TALEA.MI Price Earnings VS Forward Price EarningsTALEA.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TALEA.MI Per share dataTALEA.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

TALEA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TALEA's earnings are expected to grow with 39.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y53.93%
EPS Next 3Y39.4%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TALEA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TALEA GROUP SPA

BIT:TALEA (2/21/2025, 7:00:00 PM)

5

-0.14 (-2.72%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1%
Inst Owner ChangeN/A
Ins Owners48.71%
Ins Owner ChangeN/A
Market Cap42.00M
Analysts86.67
Price Target10.2 (104%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.05%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 11.99
P/S 0.31
P/FCF N/A
P/OCF 4.82
P/B 1.44
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.24
EYN/A
EPS(NY)0.42
Fwd EY8.34%
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)1.04
OCFY20.73%
SpS16.38
BVpS3.47
TBVpS-4.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.06%
ROE -29.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 28.25%
FCFM N/A
ROA(3y)-2.01%
ROA(5y)-1.7%
ROE(3y)-8.9%
ROE(5y)-7.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.79%
GM growth 5Y13.49%
F-Score3
Asset Turnover0.98
Health
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 202.08%
Cap/Sales 6.79%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.64
Quick Ratio 0.27
Altman-Z 1.03
F-Score3
WACC6.01%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-267.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-103.65%
EPS Next Y77.38%
EPS Next 2Y53.93%
EPS Next 3Y39.4%
EPS Next 5YN/A
Revenue 1Y (TTM)0.85%
Revenue growth 3Y27.06%
Revenue growth 5Y39.6%
Sales Q2Q%8.36%
Revenue Next Year23.61%
Revenue Next 2Y21.79%
Revenue Next 3Y17.56%
Revenue Next 5YN/A
EBIT growth 1Y-683.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year145%
EBIT Next 3Y53.62%
EBIT Next 5YN/A
FCF growth 1Y-146.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-201.08%
OCF growth 3YN/A
OCF growth 5YN/A